Liver Metastases
Conditions
Keywords
Colorectal Cancer, Liver Metastases, Breast Cancer, Gastric Cancer, Pancreas Cancer, Carcinoembryonic antigen, CAR-T, Immunotherapy
Brief summary
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.
Detailed description
Patients undergo leukapheresis from which peripheral blood mononuclear cells are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA. Cells are expanded in culture and returned to the patient by percutaneous hepatic artery infusion at specific cell doses. Prior to the first dose, each patient will undergo diagnostic angiography to verify suitable arterial anatomy. Three anti-CEA CAR-T doses per patient are planned at 1-week intervals. Low dose interleukin-2 will be given via an ambulatory infusion pump for 4 weeks. Normal liver and tumor biopsies will be obtained at the time of the initial diagnostic angiogram and during the final session following the 3rd CAR-T infusion. Patients with CEA+ liver metastases who exhibit in-liver control following CAR-T therapy who also have CEA+ primary pancreatic tumors may be eligible to receive direct intrapancreatic CAR-T retrograde venous infusions. A maximum of 2 infusions will be delivered. No additional IL-2 will be given and there will be no additional biopsies.
Interventions
BIOLOGICALanti-CEA CAR-T cells
Gene modified patient T cells
Sponsors
University of Colorado, Denver
Sorrento Therapeutics, Inc.
Roger Williams Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient with histologically confirmed diagnosis of CEA+ adenocarcinoma and liver metastases. Patient must have either histologic confirmation of the liver metastases or histologic documentation of the primary tumor and definitive radiologic evidence of liver involvement. Measurable disease is required with lesions of \> 1.0 cm by CT. Soluble CEA is not acceptable as the sole measure of disease. Limited extrahepatic disease is acceptable if confined to the lungs or peritoneal cavity. * Tumor must be CEA-expressing as demonstrated by elevated serum CEA levels (≥10ng/ml) or immunohistochemistry on a biopsy specimen. Archived tissue is acceptable for determination of CEA expression. * Patient must be at least 18 years of age. * Patient able to understand and sign informed consent. * Patient with a life expectancy of greater than four months. * Patient failed at least one line of standard systemic chemotherapy and has unresectable disease. * Patient with performance status of 0 to 1 (ECOG). * Patient with adequate organ function as defined in protocol. * Acceptable hepatic vascular anatomy as determined by CT, MR, or conventional angiography. A nuclear medicine study will be performed to document the absence of a significant hepatic-pulmonary shunt (\<20%).
Exclusion criteria
* Female patients of childbearing age will be tested for pregnancy. Pregnant patients will be excluded from the study. Males who are actively seeking to have children will be made aware of the unknown risks of this study protocol on human sperm and the need to practice birth control. * Patients with serious or unstable renal, hepatic, pulmonary, cardiovascular, endocrine, rheumatologic, or allergic disease based on history, physical exam and laboratory tests will be excluded, as outlined in section 5.2.8. * Patients with active clinical disease caused by CMV, hepatitis B or C, HIV or tuberculosis will be excluded from the study. * Patients who have had cytotoxic and/or radiation therapy within 4 weeks prior to entry into the trial or 4 weeks prior to infusion will be excluded. Patients with other concurrent malignancies will be excluded. * Patients requiring systemic steroids will be excluded. * Patients with unsuitable hepatic vascular anatomy will be excluded from the study. * Patients with extrahepatic metastatic disease beyond the lungs or abdominal/ retroperitoneal lymph nodes. * Patients with \>50% liver replacement at time of treatment will be excluded. * Previous external beam radiotherapy to the liver. * Portal vein thrombosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events | 10 weeks | To determine the safety and regimen limiting toxicity (RLT) of anti-CEA CAR-T hepatic artery infusions (HAI) via the Surefire Infusion System (SIS) for CEA-expressing liver metastases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic treatment response by PET | 10 weeks | Changes in tumor metabolic activity |
| CAR-T detection in liver tumors | 10 weeks | Quantification of CAR-T cells in liver tumor core biopsies |
| CAR-T detection in normal liver tissue | 10 weeks | Quantification of CAR-T cells in normal liver core biopsies |
| CAR-T detection in extrahepatic sites | 10 weeks | Quantification of CAR-T in blood samples |
| Radiographic treatment response by MRI | 10 weeks | Changes in tumor size |
| CEA level | 10 weeks | Measurement of serum tumor marker (ng/ml) |
| Tumor biopsy | 10 weeks | Assessment of tumor necrosis and fibrosis |
| Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS) | 10 weeks | RVI via the Surefire Infusion System (SIS) for CEA+ Primary Pancreatic Tumors Following In-liver Disease Control |
| Serum Cytokine Levels | 10 weeks | Measurement of cytokines as indicators of immune response |
Countries
United States
Outcome results
None listed